Generics of Yuhan’s True Set Tab., a triple-combination drug for hypertension with rapid sales growth, are already gearing up for competition.

True Set, a triple-combination drug that contains telmisartan, amlodipine besylate, and chlorthalidone, received approval in August 2019. Subsequently, True Set was released to the market in November following reimbursement approval.

True Set’s re-examination period is set to expire in August 22, 2025, which is a year and 8 months from now. Given these circumstances, generic companies are actively pursuing opportunities for generic entry.

The MFDS approved Jeil Pharm’s bioequivalence trial protocol for JLP-2202 on 21st.